학술논문

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Document Type
Article
Source
In The Lancet Oncology April 2017 18(4):473-485
Subject
Primary Research
Articles
Language
ISSN
1470-2045